Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ GS
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Gilead Sciences Inc

+ Add to Watchlist

GILD:US

101.0000 USD 0.0750 0.07%

As of 20:10:00 ET on 03/27/2015.

Snapshot for Gilead Sciences Inc (GILD)

Open: 101.0000 Day's Range: 100.9000 - 102.1000 Volume: 8,815,858
Previous Close: 101.0750 52wk Range: 63.5000 - 116.8300 1-Yr Rtn: +47.34%

Stock Chart for GILD

No chart data available.
  • GILD:US 101.0000
  • 1D
  • 1M
  • 1Y
101.0750
Interactive GILD Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for GILD

Current P/E Ratio (ttm) 13.6507
Estimated P/E(12/2015) 10.6003
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) 7.3989
Est. EPS (USD) (12/2015) 9.5280
Est. PEG Ratio 0.7745
Market Cap (M USD) 149,789.33
Shares Outstanding (M) 1,483.06
30 Day Average Volume 10,052,664
Price/Book (mrq) 9.8145
Price/Sale (ttm) 6.1719
Dividend Indicated Gross Yield 1.70%
Cash Dividend (USD) 0.4300
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 04/22/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for GILD

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for GILD

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. The Company's primary areas of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions.

John C MartinChairman/CEOJohn F MilliganPresident/COO
Robin L WashingtonExec VP/CFOJohn G McHutchisonExec VP
More Company Profile & Key Executives for GILD

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil